Keytruda under Priority Review for first-line squamous NSCLC
Merck & Co. Inc. (NYSE:MRK) said FDA accepted and granted Priority Review to an sBLA for Keytruda pembrolizumab plus carboplatin/paclitaxel or Abraxane nab-paclitaxel as first-line treatment of metastatic squamous non-small cell lung cancer regardless of PD-L1 expression. The PDUFA date is Oct. 30.
Merck's submission is based on data from the Phase III KEYNOTE-407 trial in which Keytruda plus chemotherapy met the primary endpoints of improving progression-free survival (PFS) and overall survival (OS) vs. chemotherapy alone (see "Phase III Squamous NSCLC Survival Readouts at ASCO for Keytruda, Tecentriq")...
BCIQ Company Profiles
BCIQ Target Profiles